Stock listing

NASDAQ:DRMA Dermata Therapeutics, Inc. Stock

Home listing (NASDAQ) of Dermata Therapeutics, Inc.

Follow Dermata Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:DRMA

$0.510 USD -0.031 (-5.7%)

Close on Nov 20, 2026

Past year -79.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.500 – $0.547 USDNov 20, 2026
Volume
26,595 sharesNov 20, 2026
Market cap
$2.52M USDAt the close on Nov 20, 2026 · price × 4.96M shares outstanding
52-week range
$0.500 – $4.660 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.50M USDMedian day 49,938 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Dermata Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:DRMA · Home$0.510 USD-0.031 (-5.7%)26,595$0.532$0.547$0.500$0.540Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DRMA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.510-0.031-5.7%$0.532$0.547$0.50026,595
$0.540-0.030-5.3%$0.570$0.597$0.53370,728
$0.570-0.028-4.7%$0.610$0.680$0.57076,545
$0.599-0.023-3.7%$0.603$0.640$0.56648,756
$0.621-0.040-6.0%$0.650$0.660$0.571160,612
$0.661-0.054-7.6%$0.709$0.709$0.66114,441
$0.715+0.000+0.1%$0.740$0.740$0.65079,870
$0.715-0.055-7.2%$0.750$0.778$0.71445,068
$0.770+0.006+0.8%$0.782$0.813$0.71936,719
$0.764+0.002+0.3%$0.757$0.836$0.73460,212
$0.762-0.093-10.9%$0.850$0.850$0.76249,938
$0.855+0.006+0.7%$0.844$0.870$0.80351,881
$0.849+0.095+12.6%$0.757$0.909$0.720224,952
$0.754-0.021-2.7%$0.771$0.819$0.744140,372
$0.775-0.066-7.9%$0.799$0.829$0.76461,673
$0.841-0.034-3.8%$0.880$0.880$0.82331,522
$0.875+0.120+15.9%$0.770$0.890$0.750169,729
$0.755+0.037+5.2%$0.736$0.770$0.673186,890
$0.718-0.063-8.1%$0.765$0.780$0.703114,084
$0.781-0.083-9.6%$0.833$0.850$0.772119,400
$0.864+0.064+8.0%$0.780$0.870$0.780137,700
$0.800-0.070-8.0%$0.850$0.890$0.782221,200
$0.870+0.010+1.2%$0.855$0.928$0.830181,000
$0.8600.0000.0%$0.848$0.970$0.760851,500
$0.860-0.050-5.5%$0.909$0.950$0.8102,517,700
$0.910+0.247+37.3%$0.769$1.180$0.766170,521,300
$0.663-0.197-22.9%$0.860$0.860$0.603350,800
$0.860-0.030-3.4%$0.890$0.900$0.84038,100
$0.890-0.130-12.7%$1.000$1.010$0.88739,600
$1.020-0.050-4.7%$1.080$1.080$1.01022,100
$1.070-0.050-4.5%$1.100$1.100$1.0507,000
$1.120-0.010-0.9%$1.140$1.140$1.1107,400
$1.130+0.020+1.8%$1.120$1.145$1.11029,600
$1.110+0.005+0.5%$1.160$1.160$1.09014,100
$1.105-0.005-0.5%$1.160$1.160$1.08017,600
$1.110+0.010+0.9%$1.080$1.130$1.06020,800
$1.100-0.030-2.7%$1.100$1.120$1.10014,700
$1.130+0.010+0.9%$1.120$1.175$1.11510,400
$1.120-0.020-1.8%$1.140$1.160$1.10025,000
$1.140-0.030-2.6%$1.150$1.200$1.13030,300
$1.170+0.050+4.5%$1.150$1.250$1.12078,100
$1.120-0.030-2.6%$1.180$1.180$1.12014,400
$1.1500.0000.0%$1.170$1.190$1.15025,800
$1.150-0.010-0.9%$1.150$1.180$1.14019,700
$1.1600.0000.0%$1.180$1.190$1.1405,600
$1.160+0.010+0.9%$1.120$1.200$1.12014,300
$1.150+0.020+1.8%$1.110$1.174$1.10025,700
$1.130-0.020-1.7%$1.160$1.187$1.06036,900
$1.150-0.040-3.4%$1.180$1.270$1.15017,700
$1.190-0.010-0.8%$1.230$1.230$1.16024,900
$1.200-0.010-0.8%$1.210$1.225$1.18016,400
$1.210-0.040-3.2%$1.240$1.280$1.21018,400
$1.250+0.040+3.3%$1.220$1.312$1.21051,100
$1.210-0.020-1.6%$1.230$1.259$1.20140,300
$1.230-0.050-3.9%$1.280$1.369$1.210101,900
$1.280-0.020-1.5%$1.310$1.310$1.25053,400
$1.300+0.010+0.8%$1.270$1.310$1.25017,400
$1.290-0.050-3.7%$1.300$1.330$1.27061,700
$1.340-0.120-8.2%$1.470$1.580$1.340103,400
$1.460-0.150-9.3%$1.590$1.590$1.46088,000
$1.610-0.110-6.4%$1.700$1.720$1.59075,000
$1.720+0.090+5.5%$1.650$1.720$1.500194,600
$1.630+0.210+14.8%$1.430$1.630$1.410214,000
$1.420+0.040+2.9%$1.380$1.470$1.360229,800
$1.380-0.090-6.1%$1.490$1.490$1.36099,200

Splits

3 splits since 2023 · NASDAQ:DRMA · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-15Consolidation
1-for-16Consolidation
Ticker
NASDAQ:DRMA
Asset type
Stock
Sector
Consumer goods
Industry
Household & personal care
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Dermata Therapeutics, Inc. news

Dermata Therapeutics, Inc. on 6ix

Sector
Consumer goods
Industry
Household & personal care
News releases
19 in the last 12 months · 93 in all · newest Nov 18, 2026 · oldest 2021
Decks
1 deck · latest Jul 12, 2021

Where Dermata Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:DRMA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:DRMABOATSUnited StatesUSD

Valuation

EV/sales −31.0× against a median of 0.7×: the lowest of 10 Household & personal care companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$2.30M USD
P/E
Loss
EV/sales
−31.0×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.7×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.22

Household & personal care: the 10 companies nearest in size, of 134 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Dermata Therapeutics, Inc. · NASDAQ:DRMAUS$2.52M−US$2.30Mn/a−31.0×n/a0.7×n/a0.0×1.22
JHS Svendgaard Laboratories Limited · NSE:JHSUS$7.48MUS$8.49Mn/a0.7×29.9×0.4×−1.1%0.1×n/a
La Savonnerie de Nyons SA · EURONEXT:MLSDNUS$7.28MUS$6.24M11.2×1.3×6.6×1.9×13.5%0.2×n/a
Miraculum S.A. · GPW:MIRUS$6.97MUS$10.23Mn/a0.8×40.6×1.0×−2.0%0.5×n/a
Caring Brands, Inc. · NASDAQ:CABRUS$6.91M−US$759,746n/an/an/a0.9×n/a0.0×0.78
Eng Kah Corp. Bhd. · MYX:ENGKAHUS$5.41MUS$1.72Mn/a0.2×n/a0.5×−28.1%0.0×n/a
Sea Mild Biotechnology Co., Ltd. · TPEX:7516US$4.16MUS$2.23M15.5×0.2×2.4×1.2×2.6%0.1×n/a
Anagenics Limited · ASX:AN1US$3.91MUS$3.55M19.2×1.0×6.6×1.4×6.0%0.0×n/a
CCA Industries, Inc. · OTC:CAWWUS$2.64MUS$2.93Mn/a0.6×n/a0.8×−6.8%0.1×0.08
Skin Laboratory Public Company Limited · SET:SKINUS$2.50MUS$827,978n/a0.2×n/a1.0×−12.0%0.0×n/a
Highlander Enterprise S.A. · NEWCONNECT:HERUS$2.14MUS$2.14Mn/a16.0×8.7×54.7×−194.8%0.0×n/a
Median of the othersUS$4.78MUS$2.58M15.5×0.7×7.7×1.0×−2.0%0.1×0.43

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.17 · 1 analyst
Revenue, year to Dec 2026
100K · 1 analyst

Team and board

Officers

OfficerRole
Gerry ProehlChairman, President, and CEO
Kyri Van HooseSenior Vice President, Chief Financial Officer
Cliff MastricolaInvestor Relations
Chris NardoSenior Vice President, Chief Development Officer
Kyra PeckaitisVice President, Marketing
Maria Bedoya Toro MuneraSenior Vice President of Regulatory Affairs and Quality Assurance

Board

DirectorRole
Gerry ProehlChairman, President, and CEO
Andrew SandlerDirector
Brittany BradrickDirector
David HaleLead Director
Kathleen ScottDirector
Steve MentoDirector
Wendell WierengaDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+0.1%
Q2 2026Aug 11, 2026 · After close+27.8%
Q1 2026May 13, 2026 · After close+3.4%
Q4 2025Mar 27, 2026−16.8%
Q3 2025Nov 14, 2025 · After close−7.5%
Q2 2025Aug 13, 2025 · After close−9.8%
Q1 2025May 7, 2025 · After close−7.1%
Q4 2024Mar 17, 2025 · After close+2.6%
Q3 2024Nov 13, 2024 · After close−3.3%
Q2 2024Aug 7, 2024 · After close+12.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close
Q4 2023Mar 21, 2024 · After close+3.8%
Q3 2023Nov 9, 2023 · After close−7.7%
Q2 2023Aug 10, 2023 · After close−2.6%
Q1 2023May 11, 2023 · After close+35.2%
Q4 2022Feb 21, 2023 · After close−4.1%
Q3 2022Nov 10, 2022 · After close+10.3%
Q2 2022Aug 15, 2022 · After close+3.4%
Q1 2022May 16, 2022 · After close−7.3%
Q4 2021Mar 28, 2022 · Before open+0.8%

Open Events

Decks

DeckKindSlidesDate
IPO Roadshow (July 2021)IPO roadshow31 slidesJul 12, 2021

Open Decks

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants) with series E and series F warrants
Announced: about US$3.4M · US$1.46 a share · Warrants at US$1.46
Insiders: Company insiders, including the CEO, CFO and a member of management, are participating at $1.47 per share and accompanying warrants, with warrant exercise price of $1.47
Use of proceeds: General corporate purposes incl. consumer research, launch of direct-to-consumer product, acquisitions, licensing and working capital
Aug 17, 2026
Private placement of shares of common stock (or pre-funded warrants) with series C and series D warrants
Closed: US$4.1M raised · US$2.04 a share · Warrants at US$2.04 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Insiders: Company insiders, including the CEO, CFO and certain members of management, participated in the offering
Use of proceeds: General corporate purposes, including consumer research, launch of OTC acne kit, acquisitions, licensing and working capital
Dec 29, 2025
Warrant exercise of common stock upon exercise of existing warrants
Announced: about US$6.2M · US$1.284 a share · Warrants at US$1.284 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co.
Use of proceeds: General corporate purposes, including research, clinical trials, technology development, licensing, acquisitions and working capital
Mar 28, 2025
Private placement of shares of common stock (or pre-funded warrants) and accompanying warrants
Closed: US$2.55M raised · US$1.27 a share · Warrants at US$1.27 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Insiders: Company insiders, including the CEO, CFO and certain board members, participated at the same price as other investors
Use of proceeds: General corporate purposes, including research, pre-clinical studies, clinical trials, licensing and working capital
Jan 23, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$7.00 a unit on Aug 12, 2021.

Price
US$7.00 a unit
Units offered
2,571,428 units
Offering size
US$18 million
Underwriters' option
Up to 385,714 more units
Underwriters
Sole Book Running Manager Maxim Group LLC, Brookline Capital Markets · In the order on the cover
Units delivered
On or about Aug 17, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceApr 2, 2021
Filed publiclyJun 10, 2021
Amended 3 timesNewest Aug 6, 2021
Shares registered with an exchangeAug 11, 2021
Declared effective by the SECAug 12, 2021
Final prospectus, with the priceAug 16, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Aug 16, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Cost of revenue3221.35K
Gross profit-322-1.35K
Research and development2.93M8.20M4.07M5.65M3.46M1.61M2.62M
Selling, general and administrative4.84M4.31M3.97M4.02M4.40M1.56M1.85M
Operating income-7.77M-12.5M-8.04M-9.67M-7.86M-3.17M-4.47M
Depreciation and amortization12.5M8.04M9.67K03221.35K
EBITDA-2420-9.66M-7.86M-3.17M-4.47M
Interest expense63.6K45.6K197.3K250.7K
Income before tax-7.56M-12.3M-7.79M-9.61M-7.90M-3.24M-4.72M
Income tax00000250.7K
Net income-7.56M-12.3M-7.79M-9.61M-7.90M-3.24M-4.72M
Earnings per share, basic-8.16-80.32-39.99-13.92-2.43-1.69-1,360.62
Earnings per share, diluted-8.16-80.32-39.99

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents7.52M3.16M7.44M6.24M10.8M530.4K1.99M
Short-term investments3.16B
Receivables8.36K12.6K
Current assets7.86M3.53M7.98M6.94M11.6M605.5K2.07M
Property, plant and equipment00322
Total assets7.86M3.53M7.98M6.94M11.6M605.5K2.07M
Accounts payable460.8K808.0K866.0K496.7K515.2K104.3K337.2K
Current liabilities1.64M1.97M1.62M922.6K1.52M3.78M1.72M
Long-term debt553.2K
Total debt0556.2K1.28M
Total liabilities1.64M1.97M1.62M922.6K1.52M3.78M2.28M
Shareholders' equity6.22M1.56M6.36M6.02M10.1M-3.18M-210.2K
Shares outstanding2.66M251.7K262.0K770.1K8.33M12.3M3.47K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-7.80M-11.2M-6.41M-8.83M-5.69M-4.03M-3.92M
Capital spending000-4000
Free cash flow-7.76M-11.2M-6.41M-8.83M-5.69M-4.03M-3.92M
Cash from financing12.1M6.89M7.61M4.28M16.0M2.57M4.73M
Dividends paid-2.29M
Share buybacks-367-828-40-40-1.00M0
Change in cash4.36M-4.28M1.20M-4.56M10.3M-1.46M812.2K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 17, 2026Current reportSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 2, 2026Big-stake noticeSEC
8-K · Current reportOct 29, 2026Current reportSEC
424B3 · ProspectusOct 21, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 21, 2026Other filingsSEC
S-3 · Registration statementOct 9, 2026Offer documentSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
25-NSEAug 17, 2026Other filingsSEC
8-K · Current reportAug 17, 2026Material contractSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
8-K · Current reportAug 5, 2026Current reportSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 4, 2026Offer documentSEC
SCHEDULE 13D · Big-stake noticeJun 1, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJun 1, 2026Other filingsSEC
424B3 · ProspectusMay 29, 2026Offer documentSEC
8-K · Current reportMay 27, 2026Management or board changeSEC
CORRESP · Letter to the SECMay 27, 2026Other filingsSEC
S-3/A · Registration statement, amendedMay 22, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 22, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 17, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 6, 2026Meeting noticeSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
8-K · Current reportFeb 25, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 23, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 18, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
8-K · Current reportFeb 3, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 2, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 30, 2026Other filingsSEC
424B3 · ProspectusJan 29, 2026Offer documentSEC
CORRESP · Letter to the SECJan 27, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 27, 2026Other filingsSEC
8-K · Current reportJan 27, 2026Current reportSEC
424B5 · ProspectusJan 27, 2026Offer documentSEC
S-3 · Registration statementJan 22, 2026Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 8, 2026Big-stake noticeSEC
DJan 7, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 2, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 30, 2025Big-stake noticeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
8-K · Current reportDec 29, 2025Material contractSEC
S-3 · Registration statementNov 21, 2025Offer documentSEC
8-K · Current reportNov 17, 2025Current reportSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
8-K · Current reportNov 7, 2025Current reportSEC
424B5 · ProspectusNov 7, 2025Offer documentSEC
8-K · Current reportSep 17, 2025Current reportSEC
8-K · Current reportSep 10, 2025Current reportSEC
8-K · Current reportAug 25, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
8-K · Current reportJul 30, 2025Current reportSEC
8-K · Current reportJul 15, 2025Meeting outcomeSEC
8-K · Current reportJul 7, 2025Current reportSEC
8-K · Current reportJun 5, 2025Current reportSEC
ARS · Annual report to shareholdersJun 2, 2025Annual reportSEC
DEFA14A · Additional proxy materialJun 2, 2025Meeting noticeSEC
DEF 14A · Proxy statementJun 2, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementMay 23, 2025Meeting noticeSEC
8-K · Current reportMay 21, 2025Current reportSEC
8-K · Current reportMay 16, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 14, 2025ResultsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 24, 2025Other filingsSEC
424B3 · ProspectusApr 23, 2025Offer documentSEC
CORRESP · Letter to the SECApr 21, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 21, 2025Other filingsSEC
S-3 · Registration statementApr 15, 2025Offer documentSEC
8-K · Current reportApr 15, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 7, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 3, 2025Big-stake noticeSEC
8-K · Current reportMar 28, 2025Material contractSEC
8-K · Current reportMar 27, 2025Current reportSEC
8-K · Current reportMar 25, 2025Current reportSEC
8-K · Current reportMar 17, 2025ResultsSEC
10-K · Annual reportMar 17, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveFeb 6, 2025Other filingsSEC
424B3 · ProspectusFeb 5, 2025Offer documentSEC
D/AFeb 4, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 3, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 3, 2025Other filingsSEC
S-3 · Registration statementJan 30, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeJan 28, 2025Big-stake noticeSEC
DJan 28, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 23, 2025Big-stake noticeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
8-K · Current reportJan 23, 2025Material contractSEC
8-K · Current reportJan 21, 2025Material contractSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 13, 2024ResultsSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
DSep 27, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 25, 2024Other filingsSEC
424B3 · ProspectusSep 24, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 23, 2024Other filingsSEC
CORRESP · Letter to the SECSep 23, 2024Other filingsSEC
S-3 · Registration statementSep 19, 2024Offer documentSEC
8-K · Current reportSep 17, 2024Material contractSEC
S-8 · Registration statement for employee plansAug 7, 2024Offer documentSEC
8-K · Current reportAug 7, 2024ResultsSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 2, 2024Current reportSEC
424B5 · ProspectusAug 2, 2024Offer documentSEC
424B3 · ProspectusJul 15, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 15, 2024Other filingsSEC
CORRESP · Letter to the SECJul 10, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 8, 2024Other filingsSEC
S-3 · Registration statementJul 3, 2024Offer documentSEC
8-K · Current reportJun 7, 2024Material contractSEC
424B5 · ProspectusJun 7, 2024Offer documentSEC
8-K · Current reportJun 5, 2024Current reportSEC
8-K · Current reportMay 24, 2024Current reportSEC
8-K · Current reportMay 17, 2024Material contractSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
8-K · Current reportMay 15, 2024Current reportSEC
8-K · Current reportMay 14, 2024Current reportSEC
8-K · Current reportMay 7, 2024Management or board changeSEC
ARS · Annual report to shareholdersMar 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialMar 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementMar 26, 2024Meeting noticeSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
PRE 14A · Preliminary proxy statementMar 1, 2024Meeting noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
8-K · Current reportJan 12, 2024Meeting outcomeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 18, 2023Other filingsSEC
424B3 · ProspectusDec 15, 2023Offer documentSEC
CORRESP · Letter to the SECDec 13, 2023Other filingsSEC
UPLOAD · Letter from the SECDec 13, 2023Other filingsSEC
DEF 14A · Proxy statementDec 8, 2023Meeting noticeSEC
S-3 · Registration statementDec 7, 2023Offer documentSEC
PRE 14A · Preliminary proxy statementNov 29, 2023Meeting noticeSEC
8-K · Current reportNov 17, 2023Material contractSEC
8-K · Current reportNov 15, 2023Current reportSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
S-8 · Registration statement for employee plansSep 14, 2023Offer documentSEC
8-K · Current reportAug 10, 2023ResultsSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 3, 2023Management or board changeSEC
EFFECT · Notice that a registration is effectiveJul 28, 2023Other filingsSEC
424B4 · ProspectusJul 27, 2023Offer documentSEC
CORRESP · Letter to the SECJul 25, 2023Other filingsSEC

This page holds 200 of 374 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Dermata Therapeutics, Inc.’s releases · as of Aug 17, 2026

Common shares
4,955,207
Fully diluted
4,955,207

Fully diluted

LineShares
Common shares4,955,207

Warrants and options

Lot
Warrants · US$2.04 · expiry not stated
Warrants · US$1.27 · expire about Jan 2030

Share count over time

CountShares
Nov 22, 20264,955,207

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Citadel32,7960.67%US$36,076Sep 30, 2026
Geode Capital20,1010.41%US$22,111Sep 30, 2026
Welch & Forbes LLC20,0000.41%US$22,000Sep 30, 2026
Hrt Financial LP19,4030.39%US$21,000Sep 30, 2026
State Street18,7470.38%US$20,622Sep 30, 2026
UBS17,1150.35%US$18,827Sep 30, 2026
Jane Street16,5890.34%US$18,248Sep 30, 2026
XTX Topco Ltd12,8770.26%US$14,165Sep 30, 2026
Citigroup Inc6,6250.13%US$7,288Sep 30, 2026
Vanguard5,4380.11%US$5,982Sep 30, 2026
All 15 holders
HolderSharesOf the companyValueAs of
Tower Research Capital LLC (TRC)313<0.01%US$344Sep 30, 2026
SBI Securities Co., Ltd.102<0.01%US$112Sep 30, 2026
Highline Wealth Partners LLC26<0.01%US$29Sep 30, 2026
JPMorgan3<0.01%US$3Sep 30, 2026
Morgan Stanley2<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund41,3210.84%US$53,717May 31, 2026
Fidelity Series Total Market Index Fund1,1060.02%US$1,438May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Scott Kathleen D.
Director
Sale11USD 1.19US$13Jun 16, 2026

Big stakes

StakeStakeSharesDateFiling
PROEHL GERALD T17.30%695KFeb 19, 2026Schedule 13D
Kyri K. Van Hoose9.00%384KMay 27, 2026Schedule 13D
Bigger Michael8.36%414KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Hale
Other companies: Oncternal Therapeutics Inc (Director · Jun 7, 2019 – Jun 20, 2024 · Past); Histogen Inc (Director · Jul 24, 2013 – Jun 27, 2019 · Past); Somaxon Pharmaceuticals Inc (Director · Apr 2, 2012 – Dec 31, 2012 · Past); Santarus Inc (Director · Mar 21, 2012 – Jan 2, 2014 · Past)
Lead Director · Since at least Aug 12, 2021
Andrew Sandler M.D.
Other companies: Alpine Immune Sciences Inc (Chief Medical Officer · Aug 17, 2022 – Jan 5, 2023 · Past); Dendreon Corp (EVP, Chief Medical Officer · Jan 13, 2014 – Feb 13, 2015 · Past)
Director · Since at least Aug 12, 2021
Brittany Bradrick
Other companies: Spectrum Pharmaceuticals Inc (Director · May 4, 2022 – Jul 31, 2023 · Past)
Director · Since at least Jan 12, 2022
Chris NardoSenior Vice President, Chief Development Officer · Since at least Jun 10, 2025
Christopher J NardoSenior VP, CDO · Since at least Aug 12, 2021
Cliff MastricolaInvestor Relations · Since at least Oct 29, 2026
Gerald T ProehlPRESIDENT, CHAIRMAN, CEO, Director · Since at least Aug 16, 2026
Gerry ProehlChairman, President, and CEO · Since at least Aug 18, 2026
Kathleen ScottDirector · Since at least Jun 10, 2025
Kyra PeckaitisVice President, Marketing · Since at least Mar 10, 2026
All 15 people
PersonSeat
Kyri Van HooseSenior Vice President, Chief Financial Officer · Since at least Jun 10, 2025
Maria Bedoya Toro MuneraSenior Vice President of Regulatory Affairs and Quality Assurance · Since at least Jun 10, 2025
Mary FisherDirector · Since at least Jan 2, 2026
Steve MentoDirector · Since at least Nov 4, 2026
Wendell WierengaDirector · Since at least Jun 10, 2025

Open People

Log in to ask 6ix AI your own questions about Dermata Therapeutics, Inc.